ArticlePain management2012
Buprenorphine implant for opioid addiction.
Article in Pain management, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 33 citations in OpenAlex.
- Information Needs for Opioid Use Disorder Treatment Using Buprenorphine Product: Qualitative Analysis of Suboxone-Focused Reddit Data.Journal of medical Internet research · 2025Article
- Dezocine and Addiction: Friend or Foe?Pharmaceuticals (Basel, Switzerland) · 2025Review
- In Vitro-In Vivo Correlation of Buprenorphine Transdermal Systems Under Normal and Elevated Skin Temperature.Pharmaceutical research · 2023Article
- Racial and Ethnic Disparities in Buprenorphine and Extended-Release Naltrexone Filled Prescriptions During the COVID-19 Pandemic.JAMA network open · 2022Article
- The Association Between Scope of Practice Regulations and Nurse Practitioner Prescribing of Buprenorphine After the 2016 Opioid Bill.Medical care research and review : MCRR · 2022Article
- Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm Neonates.Pharmaceutics · 2020Article
- Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders.Journal of substance abuse treatment · 2020Article
- Perioperative Management of a Patient Taking Suboxone® at the Time of Ambulatory Surgery.Case reports in anesthesiology · 2020Article
- Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment.American journal of preventive medicine · 2018Article
- Shelter-Based Opioid Treatment: Increasing Access to Addiction Treatment in a Family Shelter.American journal of public health · 2017Article
- Probuphine® (buprenorphine implant): a promising candidate in opioid dependence.Therapeutic advances in psychopharmacology · 2017Review
- A Perspective on Opioid Pharmacotherapy: Where We Are and How We Got Here.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2016Review
- The New Kid on the Block--Incorporating Buprenorphine into a Medical Toxicology Practice.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2016Review
- Buprenorphine implant for opioid addiction.Pain management · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
SUMMARY The buprenorphine implant (Probuphine™, Titan Pharmaceuticals, CA, USA) is a recently developed long-acting formulation of buprenorphine, which is a partial opioid agonist that is widely used in the marketed, sublingual, daily-dose form for managing opioid addiction. The new formulation uses a novel delivery system consisting of subcutaneously implanted solid matrix 'rods' made from a mixture of ethylene vinyl acetate and buprenorphine. The buprenorphine implant was developed to ensure medication compliance, eliminate misuse and abuse from diversion of sublingual buprenorphine, and increase therapeutic benefit of the medication. The implant is not a 'new' drug, but an innovative means of delivering a medication proven effective for treating opioid addiction. The implant has not yet been approved by the US FDA. The information in this review has been gleaned from research reports, documentation in the literature, and from the author's experience treating opioid-dependent patients, and involvement in clinical research examining sublingual buprenorphine and the buprenorphine implant.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.